Journal of International Oncology››2022,Vol. 49››Issue (12): 766-768.doi:10.3760/cma.j.cn371439-20220816-00151
Received:2022-08-16Revised:2022-10-14Online:2022-12-08Published:2023-01-05
"
"
"
| [1] | Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33. DOI: 10.3322/caac.21654. doi:10.3322/caac.21654 |
| [2] | Rütten H, Verhoef C, van Weelden WJ, et al. Recurrent endome-trial cancer: local and systemic treatment options[J]. Cancers (Basel), 2021, 13(24): 6275. DOI: 10.3390/cancers13246275. doi:10.3390/cancers13246275 |
| [3] | Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and posto-perative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma[J]. Lancet, 2000, 355(9213): 1404-1411. DOI: 10.1016/s0140-6736(00)02139-5. doi:10.1016/s0140-6736(00)02139-5pmid:10791524 |
| [4] | 徐兴远, 王丹波. 复发性子宫内膜癌的治疗[J]. 中国实用妇科与产科杂志, 2022, 38(5): 507-511. DOI: 10.19538/j.fk2022050108. doi:10.19538/j.fk2022050108 |
| [5] | Sapienza LG, Ning MS, de la Pena R, et al. Outcomes and toxicity after salvage radiotherapy for vaginal relapse of endometrial cancer[J]. Int J Gynecol Cancer, 2020, 30(10): 1535-1541. DOI: 10. 1136/ijgc-2020-001281. doi:10.1136/ijgc-2020-001281pmid:32376738 |
| [6] | Crosbie EJ, Kitson SJ, McAlpine JN, et al. Endometrial cancer[J]. Lancet, 2022, 399(10333): 1412-1428. DOI: 10.1016/S0140-6736(22)00323-3. doi:10.1016/S0140-6736(22)00323-3pmid:35397864 |
| [7] | 中国抗癌协会妇科肿瘤专业委员会. 子宫内膜癌诊断与治疗指南(2021年版)[J]. 中国癌症杂志, 2021, 31(6): 501-512. DOI: 10.19401/j.cnki.1007-3639.2021.06.08. doi:10.19401/j.cnki.1007-3639.2021.06.08 |
| [8] | Miller DS, Filiaci VL, Mannel RS, et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase Ⅲ trial (NRG oncology/GOG0209)[J]. J Clin Oncol, 2020, 38(33): 3841-3850. DOI: 10.1200/JCO.20. 01076. doi:10.1200/JCO.20.01076pmid:33078978 |
| [9] | 殷爱军, 李鹏, 宋坤, 等. 安罗替尼在妇科肿瘤治疗中的现状及研究进展[J]. 现代妇产科进展, 2022, 31(5): 384-388, 393. DOI: 10.13283/j.cnki.xdfckjz.2022.05.016. doi:10.13283/j.cnki.xdfckjz.2022.05.016 |
| [10] | Cui Q, Mao Y, Hu Y, et al. Anlotinib in recurrent or metastatic endometrial cancer[J]. Int J Gynecol Cancer, 2022, 32: 1147-1152. DOI: 10.1136/ijgc-2022-003345. doi:10.1136/ijgc-2022-003345 |
| [11] | Wei W, Ban X, Yang F, et al. Phase Ⅱ trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer[J]. J Immunother Cancer, 2022, 10(5): e004338. DOI: 10.1136/jitc-2021-004338. doi:10.1136/jitc-2021-004338 |
| [12] | Taurin S, Yang CH, Reyes M, et al. Endometrial cancers harbo-ring mutated fibroblast growth factor receptor 2 protein are success-fully treated with a new small tyrosine kinase inhibitor in an orthotopic mouse model[J]. Int J Gynecol Cancer, 2018, 28(1): 152-160. DOI: 10.1097/IGC.0000000000001129. doi:10.1097/IGC.0000000000001129 |
| [13] | Lin B, Song X, Yang D, et al. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1[J]. Gene, 2018, 654: 77-86. DOI: 10.1016/j.gene.2018.02.026. doi:S0378-1119(18)30155-0pmid:29454091 |
| [14] | Jablonski S. Online endometrial cancer/anlotinib/anlotinib hydroch-loride[DB/OL]. Bethesda (MD): National Library of Medicine (US). (2021-11-30)[2022-8-12]. http://www.nlm.nih.gov. |
| No related articles found! |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
